U.S. markets open in 9 hours 14 minutes
  • S&P Futures

    3,851.00
    +31.75 (+0.83%)
     
  • Dow Futures

    31,987.00
    +211.00 (+0.66%)
     
  • Nasdaq Futures

    12,455.50
    +158.25 (+1.29%)
     
  • Russell 2000 Futures

    2,218.60
    +17.80 (+0.81%)
     
  • Crude Oil

    65.51
    +0.46 (+0.71%)
     
  • Gold

    1,685.60
    +7.60 (+0.45%)
     
  • Silver

    25.42
    +0.15 (+0.58%)
     
  • EUR/USD

    1.1861
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3848
    +0.0026 (+0.19%)
     
  • USD/JPY

    109.1930
    +0.2920 (+0.27%)
     
  • BTC-USD

    53,963.06
    +3,501.87 (+6.94%)
     
  • CMC Crypto 200

    1,089.27
    +65.07 (+6.35%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,923.42
    +180.17 (+0.63%)
     

Omnicare Specialty Care Group's ACS to Provide Specialty Pharmacy Services for Bayer's Nexavar® (sorafenib) and Stivarga® (regorafenib)

CINCINNATI, March 2, 2015 - Advanced Care Scripts (ACS), a leading specialty pharmacy and clinical services platform of Omnicare`s Specialty Care Group, has been chosen to dispense Bayer`s Nexavar® (sorafenib) and Stivarga® (regorafenib) as part of their limited distribution networks.

Nexavar is an anticancer medicine indicated for hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC).

Stivarga is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, an anti-EGFR therapy. Stivarga also treats patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumor who have been previously treated with imatinib mesylate and sunitinib malate.

ACS has proven experience in successfully managing and dispensing specialty medications, making it an ideal partner for pharmaceutical manufacturers. Its expertise in providing access and reimbursement support enables an efficacious process in navigating insurance benefits and financial assistance for patients. ACS services are centrally coordinated to simplify reimbursement and delivery of these complex treatments, and increase the speed to therapy for their patient populations.

"We are extremely pleased to be part of the Bayer specialty pharmacy network," said Dennis Wilson, Vice President and General Manager of ACS. "As we continue to leverage our differentiated expertise and service offering within this growing therapeutic area, we are a compelling pharmacy solution for patients being prescribed Nexavar and Stivarga. We look forward to providing comprehensive pharmacy services for these important oncologic therapies."

About Omnicare Specialty Care Group
Omnicare Specialty Care Group (SCG) is a division of Omnicare, Inc., a Fortune 500 company and provider of comprehensive pharmaceutical services based in Cincinnati, Ohio. Omnicare SCG is a combination of synergistic tenured companies with a focused approach to pharmaceutical brand solutions. Together, Omnicare SCG brings specialists in reimbursement methods, clinicians practiced in medication therapy management for chronic disease states, and distribution channel expertise. Solutions are tailored to drive product access by solving challenges faced by patients and their caregivers, physicians, payers and manufacturers. Custom programs are led by a single management team across the organizational platforms, allowing coordination of resources and assets to support positive outcomes for our patients. For more information, visit www.omnicarescg.com.

About Advanced Care Scripts
Advanced Care Scripts, a specialty pharmacy, manages and dispenses specialty medications and products nationwide. It coordinates services beginning with the prescriber to simplify reimbursement and delivery of biotech therapies used to treat cancer, infectious diseases, auto-immune disorders, multiple sclerosis, hemophilia, and other disease states. Its customer service and comprehensive patient care model provides compliance and adherence support and cost-effective solutions for all classes of specialty medications.

# # #

Contact:
Patrick C. Lee
(513) 719-1507
patrick.lee@omnicare.com



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Omnicare via GlobeNewswire

HUG#1898287